# An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

> **NCT07161700** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Seaport Therapeutics** · enrollment: 360 (estimated)

## Conditions studied

- Major Depressive Disorder (MDD)
- Major Depressive Disorder With Anxious Distress

## Interventions

- **DRUG:** SPT-300

## Key facts

- **NCT ID:** NCT07161700
- **Lead sponsor:** Seaport Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-09-02
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07161700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07161700, "An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)". Retrieved via AI Analytics 2026-09-10 from https://api.ai-analytics.org/clinical/NCT07161700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*